Overdosing on authority: negative side effects of the FDA's proposal for generic label changes may include increased costs and liabilities.

This document cites

• Federal Cases - 762 F.Supp.2d 694 (D.Vt. 2010), 2:07-cv-82, Kellogg v. Wyeth
• Federal Cases - 29 F.3d 165 (4th Cir. 1994), 93-1627, Foster v. American Home Products Corp.
• Federal Cases - 716 F.3d 1087 (8th Cir. 2013), 12-1674, Bell v. Pfizer, Inc.
• Federal Cases - 756 F.3d 917 (6th Cir. 2014), 12-5368, In re Darvocet, Darvon, & Propoxyphene Products Liability Litigation
• Federal Cases - 62 F.Supp.3d 705 (N.D.Ill. 2014), 12 C 6403, Dolin v. Smithkine Beecham Corp.



See all quotations

• Federal Cases - 819 F.Supp.2d 1254 (S.D.Ala. 2011), C. A. 06-0282-CB-M, Barnhill v. Teva Pharmaceuticals USA, Inc.
• Federal Cases - 708 F.Supp.2d 616 (E.D.Tex. 2010), C. A. 1:09-CV-785, Finnicum v. Wyeth, Inc.
• Federal Cases - 917 F.Supp.2d 597 (N.D.Miss. 2013), C. A. 4:10-CV-099-SA-JMV, Gardley-Starks v. Pfizer, Inc.
• Federal Cases - 960 F.Supp.2d 641 (S.D.Miss. 2013), 5:11-CV-69-DCB-JMR, Chatman v. Pfizer, Inc.
• Federal Cases - 894 F.Supp.2d 1302 (D.Nev. 2012), 3:11-cv-858-RCJ-VPC, Baymiller v. Ranbaxy Pharmaceuticals, Inc.
• Federal Cases - 920 F.2d 984 (D.C. Cir. 1990), 89-5183, Abbott Laboratories v. Young
• Federal Cases - 80 F.3d 1543 (Fed. Cir. 1996), 96-1068, Merck & Co., Inc. v. Kessler
• Federal Cases - 555 U.S. 555 (2009), 06-1249, Wyeth v. Levine
• Federal Cases - 564 U.S. 604 (2011), 09-993, PLIVA, Inc. v. Mensing
• Federal Cases - 570 U.S. 472 (2013), 12-142, Mutual Pharmaceutical Co., Inc. v. Bartlett
• Federal Cases - 412 U.S. 609 (1973), 72-394, Weinberger v. Hynson, Wescott & Dunning, Inc
• Federal Cases - 442 U.S. 544 (1979), 78-605, United States v. Rutherford
• Alabama - 159 So.3d 649 (Ala. 2014), 1101397, Wyeth, Inc. v. Weeks
• Iowa - 850 N.W.2d 353 (Iowa 2014), 12-0596, Huck v. Wyeth, Inc.